Immunohistochemical expression of ICAM-1 and Cortactin as cell adhesive molecule and invasive markers in Hodgkin’s and non-Hodgkin’s lymphoma of the head and neck region (A comparative study)

Article Sidebar

PDF

Main Article Content

Zaydoon M Kasim
Wasan H Younis

Abstract

Background: Lymphomas are a group of diseases caused by malignant lymphocytes that accumulate in lymph nodes and cause the characteristic clinical features of lymphadenopathy. Intercellular adhesion molecule-1 (ICAM-1) (CD54) is a transmembrane glycoprotein belonging to the immunoglobulin superfamily of adhesion molecules. Cortactin was first identified as one of the major substrates for src kinase. because it localized to Cortical actin structures, The aims of this study was to evaluate and compare the immunohistochemical of ICAM-1 expression as cell adhesion molecule marker and Cortactin expression as invasive marker. Material and Methods: This study was performed on (68) formalin-fixed, paraffin-embedded blocks, histopathologically diagnosed as lymphoma (head and neck lesions).Immunohistochemical staining of ICAM-1and Cortactin was performed on each case of the study sample. Results: The expression of ICAM-1 was membranous and cytoplasmic, the study cases showed a 98.5% positive reaction to ICAM-1, score 2 was the most common and found in 69.1% of all cases.The expression of Cortactin was cytoplasmic, 98.5% of cases expressed positive reactions to Cortactin, score 1 was the most common and found in 42.7% of all cases. Conclusion: Although the two markers showed a higher expression rate in all lymphomas (both HL and NHL) in this study, they can't be used to differentiate between them, nor can be used to differentiate between the subtypes of both HL and NHL. The high ICAM-1positive expression clarified that in addition to its role in cell-cell and cell-stromal interactions, it participates in proliferation, differentiation and invasion of malignant lymphoma cells.The present study is the first one that used Cortactin as an invasive marker for lymphoma.

Downloads

Download data is not yet available.

Article Details

Issue

Vol. 26 No. 2 (2014)

Section

Oral Diagnosis

Licenses and Copyright

 

The following policy applies in The Journal of Baghdad College of Dentistry (JBCD):

 
# JBCD applies the Creative Commons Attribution (CC BY) license to articles and other works we publish. If you submit your paper for publication by JBCD, you agree to have the CC BY license applied to your work. Under this Open Access license, you as the author agree that anyone can reuse your article in whole or part for any purpose, for free, even for commercial purposes. Anyone may copy, distribute, or reuse the content as long as the author and original source are properly cited. This facilitates freedom in re-use and also ensures that JBCD content can be mined without barriers for the needs of research.

# If your manuscript contains content such as photos, images, figures, tables, audio files, videos, etc., that you or your co-authors do not own, we will require you to provide us with proof that the owner of that content (a) has given you written permission to use it, and (b) has approved of the CC BY license being applied to their content. We provide a form you can use to ask for and obtain permission from the owner.  If you do not have owner permission, we will ask you to remove that content and/or replace it with other content that you own or have such permission to use.Don't assume that you can use any content you find on the Internet, or that the content is fair game just because it isn't clear who the owner is or what license applies.

# Many authors assume that if they previously published a paper through another publisher, they own the rights to that content and they can freely use that content in their paper, but that’s not necessarily the case, it depends on the license that covers the other paper. Some publishers allow free and unrestricted re-use of article content they own, such as under the CC BY license. Other publishers use licenses that allow re-use only if the same license is applied by the person or publisher re-using the content. If the paper was published under a CC BY license or another license that allows free and unrestricted use, you may use the content in your JBCD paper provided that you give proper attribution, as explained above.If the content was published under a more restrictive license, you must ascertain what rights you have under that license. At a minimum, review the license to make sure you can use the content. Contact that JBCD if you have any questions about the license. If the license does not permit you to use the content in a paper that will be covered by an unrestricted license, you must obtain written permission from the publisher to use the content in your JBCD paper. Please do not include any content in your JBCD paper which you do not have rights to use, and always give proper attribution.

# If any relevant accompanying data is submitted to repositories with stated licensing policies, the policies should not be more restrictive than CC BY.

# JBCD reserves the right to remove any photos, captures, images, figures, tables, illustrations, audio and video files, and the like, from any paper, whether before or after publication, if we have reason to believe that the content was included in your paper without permission from the owner of the content.

How to Cite

1.
Kasim ZM, Younis WH. Immunohistochemical expression of ICAM-1 and Cortactin as cell adhesive molecule and invasive markers in Hodgkin’s and non-Hodgkin’s lymphoma of the head and neck region (A comparative study). J Bagh Coll Dent [Internet]. 2014 Jun. 15 [cited 2024 Dec. 22];26(2):103-10. Available from: https://jbcd.uobaghdad.edu.iq/index.php/jbcd/article/view/458